Thyroid dysfunction and cardiological management in patients receiving amiodarone;Disfunção tireoidiana e conduta dos cardiologistas em pacientes usando amiodarona

Arquivos Brasileiros de Cardiologia

Volumn 82, Issue 6, 2004, Pages 523-532

  Fuks, Anna Gabriela ^a,b,c   Vaisman, Mário ^a,b   Buescu, Alexandru ^a,b  

^a UFRJ/Hosp Cardiol Laranjeiras ^*

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c NONE   (Brazil)

Author keywords

Amiodarone; Hypothyroidism; Thyroid dysfunction

Indexed keywords

AMIODARONE; LIOTHYRONINE; THYROID ANTIBODY; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; FEMALE; FOLLOW UP; FREE THYROXINE INDEX; HUMAN; HYPOTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; THYROID DISEASE; THYROID FUNCTION; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

EID: 3242665417     PISSN: 0066782X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Unger J, Lambert M, Jonckheer MH, Denayer P. Amiodarone and the thyroid: pharmacological, toxic and therapeutic effects. J Intern Med 1993; 233: 435-43.
2. Loh KC. Amiodarone-induced thyroid disorders: a clinical review. Postgraduate Med J 2000; 76: 133-40.
3. Pichler WJ, Schindler L, Stäubli M, Stadler BM, de Weck AL. Anti-amiodarone antibodies: Detection and relationship to the development of side effects. Am J Med 1988; 85: 197-202.
4. Beddows SA, Page SR, Taylor AH et al. Cytotoxic effects of amiodarone and desthylamiodarone on human thyrocytes. Biochem Pharmacol 1989; 38: 4397-403.
5. Surks MI, Slevert R. Drugs and thyroid function. N Eng Med 1995; 333: 1688-94.
6. Figge HL, Figge J. The effects of amiodarone on thyroid hormone function: A review of the physiology and clinical manifestations. J Clin Pharmacol 1990; 30: 588-95.
7. Tavackoli S, Stouffer GA, Sheahan RG. Amiodarone-induced thyrotoxicosis. Am J Med Sci 1997; 314: 97-100.
8. Harjai KJ, Licata AA. Effects of Amiodarone on Thyroid Function. Ann Intern Med 1997; 126: 63-73.
9. Daniels GH. Amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 2001; 86: 3-8.
10. Souza CI, Burch HB. Amiodarone-induced thyroid dysfunction. Endocrinologist 1999; 9: 216-27.
11. Binz K, Burger A, Valloton MB. Amiodarone et function thyroidienne: quelle attitude pratique? Schweiz Med Wochenschr 1998; 128: 1051-8.
12. Jaggarao NS, Sheldon J, Grundy EN, Vincent R, Chamberlain DA. The effects of amiodarone on thyroid function. Postgraduate Med J 1982; 58: 693-6.
13. Shukla R, Jowett NI, Thompson DR, Pohl JE. Side effects with amiodarone therapy. Postgraduate Med J 1994; 70: 492-8.
14. Thorne SA, Barnes I, Cullinan P, Somerville J. Amiodarone-associated thyroid dysfunction - Risk factors in adults with congenital heart disease. Circulation 1999; 100: 149-54.
15. Tisdale JE, Follin SL, Ordelova A, Webb CR. Risk factors for the development of specific noncardiovascular adverse effects associated with amiodarone. J Clin Pharmacol 1995; 35: 351-6.
16. Trip MD, Wiersinga WM, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991; 91: 507-11.
17. Borowski GD, Garofano CD, Rose LI et al. Effect of long-term amiodarone therapy on thyroid hormone levels and thyroid function. Am J Med 1985; 78: 443-50.
18. Harris L, McKenna WJ, Rowland E. Side effects of long-term amiodarone therapy. Circulation 1983; 67: 45-51.
19. Wiersinga WM, Trip MD. Amiodarone and thyroid hormone metabolism. Postgraduate Med J 1986; 62: 909-14.
20. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services: Screening for Thyroid Disease. Baltimore: Willians & Wilkins, 1996.
21. Wang C, Crapo LM. Epidemiology and decision making. Endocrinol Metab Clin N Am 1997; 26: 189-218.
22. Albert SG, Alves LE, Rose EP. Thyroid dysfunction during chronic amiodarone therapy. J Am Coll Cardiol 1987; 1: 175-83.
23. Singh BN, Phil D, Nademanee K. Amiodarone and thyroid function: Clinical implications during antiarrythmic therapy. Am Heart J 1983; 106: 857-69.
24. Barros MA, Maciel RM. Estudo prospectivo dos efeitos da amiodarona na função tiroidiana de pacientes chagásicos em área de deficiência de iodo. Rev Soc Bras Med Trop 1994; 27: 149-55.
25. Martino E, Aghini-Lombardi F, Mariotti S et al. Amiodarone iodine-induced hypothyroidism: Risk factors and follow-up in 28 cases. Clin Endocrinol 1987; 26: 227-37.
26. Mechlis S, Lubin E, Laor J, Margaliot M, Strasberg B. Amiodarone-induced thyroid gland dysfunction. Am J Cardiol 1987; 59: 833-5.
27. Amico JA, Richardson V, Alpert B, Klein I. Clinical and chemical assessment of thyroid function during therapy with amiodarone. Arch Intern Med 1984; 144: 487-90.
28. Sanmartí A, Permanyer-Miralda G, Castellanos JM, Foz-Sala M, Galard RM, Soler-Soler J. Chronic administration of amiodarone and thyroid function: A follow-upstudy. Am Heart J 1984; 108: 1262-8.
29. Helfand M, Redfern CC. Screening for thyroid disease: An update. Ann Intern Med 1998; 129: 144-58.
30. Ladenson PW, Singer PA, Ain KB et al. American Thyroid Association Guidelines for detection of thyroid dysfunction. Arch Intern Med 2000; 160: 1573-5.
31. Vanderpump MP, Tunbridge WM. The epidemiology of thyroid disease. In: WERNER and INGBAR's. The Thyroid. Philadelphia: Lippincott-Raven, 1996; 26: 474-82.
32. Tunbridge WM, Vanderpump MP. Population screening for autoimmune thyroid disease. Endocrinol Metab Clin N Am 2000; 29: 239-53.
33. Martino E, Safran M, Aghini-Lombardi F et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984; 101: 28-34.
34. Hak AE, Pols HA, Visser TJ. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam study. Ann Intern Med 2000; 123: 270-8.
35. Tunbridge WM, Evered DC, Hall R et al. The spectrum of thyroid disease in a community: The Whickham Survey. Clin Endocrinol (Oxf) 1977; 7: 481-93.
36. Hawthorne GC, Campbell NP, Geddes JS et al. Amiodarone induced hypothyroidism. Arch Intern Med 1985; 145: 1016-9.
37. Marqusee E, Haden ST, Utiger RD. Subclinical thyrotoxicosis. Endocrinol Metab Clin N Am 1997; 27: 37-49.
38. Newman CM, Price A, Davies DW, Gray TA, Weetman AP. Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy. Heart 1998; 79: 121-7.
39. Ayala AR, Danese MD, Ladenson PW. When to treat mild hypothyroidism. Endocrinol Metab Clin N Am 2000; 29: 399-415.
40. Biondi B, Fazio S, Palmieri EA et al. Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J Clin Endocrinol Metab 1999; 84: 2064-7.
41. Samuels MH. Subclinical thyroid disease in elderly. Thyroid 1998; 8: 803-12.
42. Foresti V, Pepe R, Parisio E, Scolari N, Zubani R, Bianco M. Antithyroid antibodies during amiodarone treatment. Acta Endocrinologica (Copenh) 1989; 121: 203-6.
43. Machado HB, Silva ME, Pinho B. Long-term amiodarone theraphy and antithyroid antibodies. Am J Cardiol 1992; 69: 971-2.
44. Martino E, Aghini-Lombardi F, Bartalena L et al. Enhanced susceptibility to amiodarone-induced hypothyroidism in patients with thyroid autoimmune disease. Arch Intern Med 1994; 154: 2722-6.
45. Ladenson PW. Recognition and management of cardiovascular disease related to thyroid dysfunction. Am J Med 1990; 88: 638-41.
46. Hilleman D, Miller MA, Parker R, Doering P, Pieper JA. Optimal management of amiodarone therapy: Efficacy and side effects. Pharmacotherapy 1998; 18 (S): 138-45.
47. Klee GG, Hay ID. Biochemical testing of thyroid function. Endocrinol Metab Clin N Am 1997; 26: 763-75.
48. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev 2001; 22: 240-54.